Belite Bio (BLTE) Competitors

Moderna currently has a consensus target price of $35.73, suggesting a potential downside of 23.50%. Belite Bio has a consensus target price of $202.33, suggesting a potential upside of 31.06%. Given Belite Bio's stronger consensus rating and higher possible upside, analysts clearly believe Belite Bio is more favorable than Moderna.

Belite Bio has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Belite Bio's return on equity of -19.49% beat Moderna's return on equity.

75.3% of Moderna shares are owned by institutional investors. Comparatively, 0.5% of Belite Bio shares are owned by institutional investors. 10.8% of Moderna shares are owned by insiders. Comparatively, 13.3% of Belite Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Belite Bio has lower revenue, but higher earnings than Moderna. Belite Bio is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

In the previous week, Moderna had 41 more articles in the media than Belite Bio. MarketBeat recorded 53 mentions for Moderna and 12 mentions for Belite Bio. Belite Bio's average media sentiment score of 0.26 beat Moderna's score of 0.04 indicating that Belite Bio is being referred to more favorably in the news media.

Moderna has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500. Comparatively, Belite Bio has a beta of -1.19, meaning that its share price is 219% less volatile than the S&P 500.

Belite Bio has lower revenue, but higher earnings than Viatris. Belite Bio is trading at a lower price-to-earnings ratio than Viatris, indicating that it is currently the more affordable of the two stocks.

In the previous week, Belite Bio had 6 more articles in the media than Viatris. MarketBeat recorded 12 mentions for Belite Bio and 6 mentions for Viatris. Viatris' average media sentiment score of 0.59 beat Belite Bio's score of 0.26 indicating that Viatris is being referred to more favorably in the media.

79.9% of Viatris shares are owned by institutional investors. Comparatively, 0.5% of Belite Bio shares are owned by institutional investors. 0.3% of Viatris shares are owned by company insiders. Comparatively, 13.3% of Belite Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Belite Bio has a net margin of 0.00% compared to Viatris' net margin of -24.58%. Viatris' return on equity of 18.11% beat Belite Bio's return on equity.

Viatris currently has a consensus price target of $14.67, suggesting a potential downside of 5.57%. Belite Bio has a consensus price target of $202.33, suggesting a potential upside of 31.06%. Given Belite Bio's stronger consensus rating and higher probable upside, analysts clearly believe Belite Bio is more favorable than Viatris.

Viatris has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500. Comparatively, Belite Bio has a beta of -1.19, indicating that its stock price is 219% less volatile than the S&P 500.

Belite Bio presently has a consensus price target of $202.33, suggesting a potential upside of 31.06%. Genmab A/S has a consensus price target of $39.07, suggesting a potential upside of 41.94%. Given Genmab A/S's stronger consensus rating and higher possible upside, analysts plainly believe Genmab A/S is more favorable than Belite Bio.

Genmab A/S has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

In the previous week, Genmab A/S had 2 more articles in the media than Belite Bio. MarketBeat recorded 14 mentions for Genmab A/S and 12 mentions for Belite Bio. Genmab A/S's average media sentiment score of 0.72 beat Belite Bio's score of 0.26 indicating that Genmab A/S is being referred to more favorably in the news media.

0.5% of Belite Bio shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by company insiders. Comparatively, 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Belite Bio has a beta of -1.19, indicating that its share price is 219% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500.

Genmab A/S has a net margin of 25.89% compared to Belite Bio's net margin of 0.00%. Genmab A/S's return on equity of 17.35% beat Belite Bio's return on equity.

In the previous week, Summit Therapeutics had 8 more articles in the media than Belite Bio. MarketBeat recorded 20 mentions for Summit Therapeutics and 12 mentions for Belite Bio. Belite Bio's average media sentiment score of 0.26 beat Summit Therapeutics' score of 0.19 indicating that Belite Bio is being referred to more favorably in the media.

Belite Bio has a beta of -1.19, indicating that its share price is 219% less volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -1.25, indicating that its share price is 225% less volatile than the S&P 500.

Belite Bio's return on equity of -19.49% beat Summit Therapeutics' return on equity.

Belite Bio is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

0.5% of Belite Bio shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by company insiders. Comparatively, 83.5% of Summit Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Belite Bio presently has a consensus price target of $202.33, suggesting a potential upside of 31.06%. Summit Therapeutics has a consensus price target of $27.58, suggesting a potential upside of 57.26%. Given Summit Therapeutics' higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than Belite Bio.